Q4 EPS Forecast for Bausch Health Cos Lifted by Analyst

Bausch Health Cos Inc. (NYSE:BHC) – Zacks Research boosted their Q4 2026 earnings per share estimates for Bausch Health Cos in a note issued to investors on Friday, September 26th. Zacks Research analyst Team now expects that the company will earn $1.14 per share for the quarter, up from their previous estimate of $1.13. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q1 2027 earnings at $0.88 EPS and FY2027 earnings at $4.38 EPS.

Bausch Health Cos (NYSE:BHC) last posted its earnings results on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.97 by ($0.07). Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. The firm had revenue of $2.57 billion during the quarter, compared to analyst estimates of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS.

Separately, Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 20th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Bausch Health Cos currently has a consensus rating of “Hold” and a consensus price target of $9.00.

Bausch Health Cos Price Performance

Bausch Health Cos stock opened at $6.49 on Monday. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 141.90. The company has a market capitalization of $2.40 billion, a price-to-earnings ratio of 24.96 and a beta of 0.48. The stock’s 50 day moving average is $6.92 and its 200-day moving average is $6.06. Bausch Health Cos has a 12 month low of $4.25 and a 12 month high of $9.85.

Institutional Investors Weigh In On Bausch Health Cos

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cary Street Partners Financial LLC bought a new stake in Bausch Health Cos during the first quarter worth $27,000. SBI Securities Co. Ltd. lifted its stake in Bausch Health Cos by 244.2% during the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company’s stock worth $27,000 after purchasing an additional 3,001 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Bausch Health Cos during the first quarter worth $27,000. Russell Investments Group Ltd. increased its holdings in shares of Bausch Health Cos by 65.9% during the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after buying an additional 3,106 shares in the last quarter. Finally, Wealthquest Corp acquired a new position in shares of Bausch Health Cos during the first quarter worth $58,000. 78.65% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Bausch Health Cos news, Director John Paulson bought 34,721,118 shares of the business’s stock in a transaction on Thursday, August 14th. The stock was purchased at an average cost of $9.00 per share, for a total transaction of $312,490,062.00. Following the completion of the purchase, the director directly owned 70,755,869 shares of the company’s stock, valued at approximately $636,802,821. This trade represents a 96.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders acquired 37,964,167 shares of company stock worth $333,757,793 in the last three months. 19.97% of the stock is owned by corporate insiders.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.